<<

. 3
( 3 .)



eoia eiaeaeoi?ia OIA–2 a a?oiiao aunieiai ea?aeiaaneoey?iiai ?enea,
11. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a methaanalysis and sys-
ia aucuaaao niiiaiee [112]. Eaeiau aie?iu auou i?iaie?eoaeuiinou
tematic review of randomizes controlled trials. Am. J. Med., 1999; 107 (6A): 48S–54S.
yoeo eniuoaiee e eiee?anoai iaoeaioia aey iieo?aiey ?acoeuoaoia, ni- 12. Feuba DA. Gastrointestinal safety and tolerability of non–selective nonsteroidal
ioaaonoao?ueo e?eoa?eyi «iaaeoeiu, iniiaaiiie ia aieacaoaeunoaao», anti–inflammatory agents and cycloxygenase–2 selective inhibitors. Clevelend Clinic J
Med 2002; 69 (Suppl 10): SI–31–SI–39.
ia ynii. N iaoae oi?ee c?aiey, ??acia?iua ia?aie?aiey i?eiaiaiey
13. Menter DG. Cycloxygenase 2 selective inhibitors in cancer treatment and prevention.
IIAI e eiaeaeoi?ia OIA–2 (a ionoonoaea aeuoa?iaoeau) eee aeeoaeuiay
Expert Opin Invest Drugs. 2002; 11: 1749–1764
i?ioaao?a eniuoaiee e ?aaeno?aoee «iiauo» IIAI nie?a?o ea?anoai
14. Etiminan M, Gill S, Samii A. Effect of non–steroidal anti–inflammatory drugs on risk
iaaeoeineie iiiiue iaoeaioai, no?aaa?ueo ino?uie e o?iie?aneeie of Alzheimer`s disease: systemic review and meta–analysis of observational studies. BMJ
aieyie ?acee?iie i?e?iau. 2003; 327: 128–131
15. Szekely CA, Thorne JE, Zandi PP et al. Nonsteroidal anti–inflammatory drugs for the
Iu n?eoaai, ?oi ia aii?in i oii, neaaoao ee nio?aiyou ca?aae-
prevention of Alzheimer`s disease: a systemic review. Neuroepidemiology 2004; 23:
no?e?iaaiiua a ?innee eiaeaeoi?u OIA–2 (oaeaeienea, iaeiene-
159–169.
eai, ieianoeea), neaaoao ioaaoeou iiei?eoaeuii. Yoi niaiaaaao n
16. Merk. Merck announces voluntary withdrawal of Vioxx. Sept 30, 2004.
oi?eie c?aiey iiiaeo aaoi?eoaoiuo ?aaiaoieiaia e niaoeaeenoia a?o- 17. Bresalier R, Sandler RS, Quan H, et al. for the Adenomatous Polyp Prevention on
aeo iaeanoae iaaeoeiu (aee??ay ea?aeieiaia), ii iiaie? eioi?uo Vioxx (APPROVEe) Trial Investigators. Cardiovascular events associated with rofecoxib
in a colorectal adenoma chemoprevention trial. New Engl J Med 2005; 352
iieuca io i?eiaiaiey yoeo i?aia?aoia i?aainoiaeo ?ene, naycaiiue n
18. Solomon SD, McMurray JJV, Pfeffer MA, et al., for the Adenoma Prevention with


389

13, 7, 2005
oOaeCOa a aOaAeeiCe
Celecoxib (APC) Study Group. New Engl J Med 2005; 352 cyclooxygenase–2 inhibitors and acute myocardial infarction in older adults. Circulation
19. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 2004; 109: 2068–73
inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass 52. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX–2 selective
surgery. J Thorac Cardiovasc Surg 2003; 125: 1881–1492. non–steroidal anti–inflammatory drugs and risk of serious coronary heart disease. Lancet
20. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX–2 inhibitors 2002; 360:1071–73
parecoxib and valdecoxib after cardiac surgery. New Engl J Med 2005; 352 53. Mamdani M, Juuurkin DN, Lee DS, et al. Cyclo–oxygenase–2 inhibitors versus
21. Furberg CD, Psaty BM, FitzGerald CA. Parecoxib, valdecoxib, and Cardiovascular risk. non–selective non–steroidal anti–inflammatory drugs and congestive heart failure out-
Circulation 2005; 111: 249 comes in eldery patients: a population–based cohort study. Lancet 2004; 363:
22. Farkouh ME, Kirshner H, Harrington RA. Comparison of lumiracoxib with naproxen 1751–1756
and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TAR- 54. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden
GET), cardiovascular outcomes: randomized controlled trial. Lancet. 2004; 364: 675–684 cardiac death in patients treated with cyclo–oxygenase 2 selective and non–selective
23. Topol EJ, Falk GW. A coxib a day won`t keep the doctor away. Lancet 2004; 364: non–steroidal anti–inflammatory drugs: nested case control–study. Lancet 2005; January
639–640. 25, http://image.thelancet.com/extras/05art1005web.pdf
24. Editorial. Vioxx: an unequall partnership between safety and efficacy. Lancet 2004; 55. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2
364: 1287–1288 inhibitors and naproxen on short term risk of acute myocardial infarction in the elderly.
25. Langton PE, Hankey GJ, Eikelboom JW. Cardiovascular safery of rofecixib (Vioxx): Arch Intern Med 2003; 163: 481–86
lessons learned and unanswered questions. MJA 2004; 181: 524–525 56. Shaya FT, Blume SW, Blanchette CM, et al. Cardiovascular risk of selective cycloxy-
26. Dieppe PA, Ebrahim S, Juni P. Lessons from the withdrawal of rofecoxib. BMJ 2004; genase–2 inhibitors compared to other nonsteroidal anti–inflammatory agents: an obser-
329: 867–868 vational study of a Medicaid population. Pharmacoepidemiol Drug Saf 2004; 13:S234.
27. Topol EJ. Arthritis Medicines and cardiovascular events – «House of coxibs» JAMA 57. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib
2005; 293: 366–368 have different odds of nonfatal myocardial infarction Ann Intern Med 2005; 142
28. Oberholzer–Gee F, Inamdar SN. Merck`recall of rofecoxib – a strategic perspective. N 58. Garcia Rodriguez LA. The effect of NSAIDs on the risk of coronary heart disease:
Engl J Med 2004; 351: 2147–2149. fusion of clinical pharmacology and pharmacoepidemylogic data. Clin Exp. Rheumatol.
29. Topol EJ. Failinh the public health – rofecoxib, Merck, and the FDA. N Engl J Med 2001; 19 (suppl. 25): S41–S45
2004; 351:1707–1709 59. Garcia Rodriguez LAC, Varas–Lorenz C, Maguire A, Gonzalez–Perez A. Nonsteroidal
30. Maxwell SRJ, Webb DJ. COX–2 selective inhibitors – important lessons learned. anti–inflammatory drugs and the risk of myocardial infarction in the general population.
Lancet 2005. Circulation 2004; 109: 3000–3006
31. Lipsky PE, Brooks P, Crofford LJ, et al. Unresolved issues in the role of cyclooxyge- 60. FDA statement on naproxen. http://www.fda.gov/bbs/topics/news/2004/
nase–2 in normal physiologic process and disease. Arch Intern Med 2000; 160: 913–920. NEW01148.httm2004.
32. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with 61. Layton D, Hughes K, Harris S, Shakir SA. Comparison of the incidence rates of throm-
selective COX–2 inhibitors. JAMA 2001; 286: 954–95 boembolic events reported for patients prescribe celecoxib and meloxicam in general
33. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovas- practice in Englend using Prescribe–Events Monitoring (PEM) data. Rheumatology
cular disease. A reappraisal. Arthritis Rheum 2003; 48: 12–20 (Oxford), 2003
34. Hankey GJ, Eikelboom JW. Cyclooxygenase–2 inhibitors. Are they really atherothrom- 62. Layton D, Heeley E, Hughes K, Shakir SA. Comparison of the incidence rates of
botic, and if not, why not? Stroke 2003; 34: 2736–2740 thromboembolic events reported for patients prescribe rofecoxib and meloxicam in gen-
35. cOOIO‚ O.a. nEIIOOIOE„AIA 2 E I?EO‚OIUI??I? OUOIO„E?. eA??A 2004; eral practice in Englend using Prescribe–Events Monitoring (PEM) data. Rheumatology
4: 209–212 (Oxford), 2003
36. cOOIO‚ O.a. AII?„AUE?AOI? UA?OE? ‚ ?A‚IUOIO„EE. eUUA?AOU‚EA IAEU 63. Altman R, Luciardi HL, Muntaner J., et al. Efficacy of assessment of meloxicam. A
e?EIIOE E i?E·OE. aIEI. i?I. iA?OE? 2003; 12 (3): 64–69. preferential COX–2 inhibitor in acute coronary syndromes without ST–segment elevation,
37. McAdam BF, Catella–Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacy- the NUT–2 pilot study. Circulation 2002; 106: 191–195
clin by cyclooxygenase (COX)–2: the human pharmacology of a selective inhibitors of 64. White WB, Strand V, Richards R, Whelton A. Efets of the cyclooxygenase–2 specific
COX–2. PNAS 1999; 96: 272–277 inhibitor valdecoxib versus nonsteroidal anti–inflammatory agents and placebo on car-
38. Cheng Y, Austin SC, Rocca B., et al. Role of prostacyclin in the cardiovascular diovascular thrombotic events in patients with arthritis. Amer J Therapeutics 2004; 11:
response to thromboxane A2. Science 2002; 296: 539–541 244–250
39. Targum SL. Review of cardiovascular safety database for Vioxx, Feb 1, 2001. 65. Livio M, Del Maschio A, Certelli C, de Gaetano G. Indomethacin prevents the long last-
http://fda.gov/ohrms/dockets/ac/o1/briefing/3677b1_cardiol.pdf ing inhibitory effect of aspirin on human platelet cyclooxygenase activity. Prostaglandins
40. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective 1982; 23: 787–796.
cyclooxygenase–2 inhibitors. Arthritis Rheum (Arthritis Care&Res) 2002; 47:349–355. 66. Rao GH, Johnson GG, Reddy KR, White JG. Ibuprofen protects platelet cycloxygenase
41. Konstam MA, Weir MR, Reicin A, Gertz BJ. Cardiovascular thrombotic evebts in con- from irreversible inhibition by aspirin. Atherosclerosis 1983; 3: 383–388
trolled trials of rofecoxib. Circulation 2001; 104: 2280–2288. 67. eatella–Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the
42. Reicin AS, Shapiro D, Sperlong RS et al. Comparison of cardiovascular thrombotic antiplatelet effect of aspirin. N Engl J Med 2001; 345: 1809–1817
events in patients with osteoarthritis treated with rofecoxib versus nonselective nons- 68. Van Solingen R.M., Rosenstein E.D., Mihailescu G., et al. Comparison of the effects
teroidal anti–inflammatory druds (ibuprofen, diclofenac and nabumeton). Am Cardiol. of ketoprofen on platelet function in the presence and absence of aspirin Am. J. Med.,
2002; 89: 204–209. 2001; 111: 285–289
43. Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX–2 inhibition and cardiovas- 69. Ouellett M, Riendeau D, Percival D. A high level of cyclooxygenase–2 inhibitor selec-
cular effects: a review of the rofecoxib development program. AHJ 2003; 146: 591–604 tivity is associated with a reduced intereference of platelet cyclooxygenase–1 inactivation
44. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in by aspirin. PNAS 2001; 98: 14583–14588
patients treated with celecoxib, a cyclooxygenase–2 specific inhibitor, versus ibuprofen 70. Greenberg H, Gottesdiener K, Huntington M, et al. A new cyclooxygenase–2 inhibitor,
or diclofenac. Am J Cardiol 2002; 89: 425–430 rofecoxib (VIOXX), did not alter the antiplatelet effects of low–dose aspirin in healthy vol-
45. Vane JB. Back to an aspirin a day. Science 2002; 296: 474–475 unteers. J Clin Pharm 2000; 40: 1509–1515
46. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection 71. Wilner KD, Rushing M, Walden C, et al. Celecoxib does not affect the antiplatelet
against acute myocardial infarction. Arch Intern Med 2002; 162; 1111–1115 activity of aspirin in healthe volunteers. J Clin Pharm 2002; 42: 1027–1030
47. Solomon DH, Glynn RJ, Levone R, et al. Nonsteroidal anti–inflammatory drug use and 72. Kurth T, Hennekens CH, Buring JE, Gaziano JM. Aspirin, NSAIDs, and COX–2
acute myocardial infarction Arch Intern Med 2002; 162: 1099–1104 inhibitors in cardiovascular disease; possible interactions and implications for treatment
48. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascu- of rheumatoid arthritis. Curr Rheum Reports 2004; 6: 351–356.
lar events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 73. MacDonald TN, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet
2002; 162: 1105–1110 2003; 361: 573–574
49. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, mono- 74. Kurth T, Glyn RJ, Walker AM, et al. Inhibition of clinical benefit of aspirin on first
cyte, and vascular cyclooxygenase inhibition by naproxen and low–dose aspirin in myocardial infarction by non–steroidal anti–inflammatory drugs. Circulation 2003; 108:
healthy subjects. Circulation 2004; 109: 1468–1471 1191–1195
50. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: 75. Curtis JP, Wang Y, Portnay EL, et al. Aspirin, ibuprofen, and mortality after myocar-
cumulative meta–analysis. Lancet 2004; 4 dial infarction. Br Ned J 2003; 164: 852–856
51. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective 76. Kimmel SE, Strom BL. Giving aspirin and ibuprofen after myocardial infarction Br



390 13, 7, 2005
Med J 2003; 327: 1298–1299 tial hypertension. J Hypertension 2003; 21: 1663–1667
77. Patel TN, Goldberg KC. Use of aspirin and ibuprofen compared with aspirin alone and 105. Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase–2–specific inhibitors and
risk of myocardial infarction. Arch Intern Med 2004; 164: 852–856 cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older
78. Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non–aspirin hypertensive osteoarthritic patients. Am J Ther 2001; 8: 85–96
non–steroidal anti–inflammatory medications on the risk of nonfatal myocardial infarction 106. White WB, Kent J, Taylor A, et al. Effects of celecoxib on ambulatory blood pres-
and their interaction with aspirin. J Am Coll Cardiol 2004; 43: 985–990. sure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39: 929–934
79. Fisher LM, Schlinger RG, Matter CM, et al. Discontinuation of nonsteroidal 107. Whelton A, White WB, Bello AE, et al. SUCCESS–VII Investigators. Effects of cele-
anti–inflamatory drug therapy and risk of acute myocardial infarction. Arch Intern Med coxib and rofecoxib on blood pressure and edema in patients> or ==65 years of age
2004; 164: 2472–2476 with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90: 959–963
80. cOOIO‚ O.a. e?O·IAI UA?OU?OI·OA ‚ ?A‚IUOIO„EE. CAOUIEI eAac 2003; 7: 108. Sowers JR, White WB, Pitt B, et al. for the Celecoxib Rofecoxib Efficacy and safe-
6–10. ty in Co–morbidities Evaluation Trial (CRESCENT) Investigators. The effect of
81. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in cyclooxygenase–2 inhibitors and nonsteroidal anti–inflammatory therapy on 24–hour
women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303–1307 blood pressure in hypertensive patients with osteoarthritis and type 2 diabetes melli-
82. Fischer LM, Schlienger RG, Matter C, et al. Effect of rheumatoid arthritis or systemic tus. Arch Intern Med 2005; 165:161–168
lupus erythematosus on the risk of first–time acute myocardial infarction. Am J Cardiol 109. Jolllis JG, Ancukiewicz M, DeLong ER, et al. Discordance of databases designed
2004; 93: 198–200 for claims payment versus clinical information system. Implications for outcomes
83. Belton O, Fitzgerald DJ. Cycloxygenase isoform and atherosclerosis. Expert reviews research. Ann Inyern Med 1993; 119: 844–850.
in molecular medicine. http//www.expertreviews.org/ 110. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with
84. Cippollone F, Rocca B, Patrono C. Cyclooxygenase–2 expression and inhibition in cycloxygenase–2 inhibitors; a population study of eldery adults. Arch Intern Med 2005;
atherothrombosis. Arteriol Thromb Vasc Biol 2004; 24: 246–255 142.
85. Linton MF, Fazio S. Cyclooxygenase–2 and inflammation in atherosclerosis. Curr Opin 111. Shaya FT, Blume SW, Blanchette CM, et al. Selective cycloxygenase inhibition and
Pharmacol 2004; 4: 116–129 cardiovascular effects. Arch Intern Med 2005; 165: 181–186.
86. cOOIO‚ O.a. aIIUIOIO„E?AOIEA I?IA?? UA?OOIIA?OA. iA?OA‚U ??E‚ 2002; 112. New Release; Pfizer to sponsor major new Celebrex clinical trial/ As part of an
5, 80–85 ongoing research program, study will evaluate potential cardiovascular benefits.
87. Chenevard R., Hurlimann D., Bechir M., et al. Selective COX–2 inhibition improves October 18. 2004
endothelial function in coronary artery disease. Circulation 2003; 107:405–409 113. Aw T–J, Haas SJ, Liew D, Krum H. Meta–analysis of cyclooxygenase–2 inhibitors
88. Verma S Rai SR, Shewchuk L et al. Cyclooxygenase–2 blocade does not impare and their effects on blood pressure. Arch Intern Med 2005; 165:1–7
endothelial vasodilatator function in healthy volunteers: randomized evaluation of rofe- 114. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX–2
coxib versus naproxen on endothelium–dependent vasodilatation. Circulation 2001; 104: specific inhibition and hypertension. Hypertension 2004; 44: 140–145.
2879–2882 115. Arthritis Advisory Committee–FDA Briefing Information, NDA 21–042/S007,
89. Title LM, Giddens K, McInerney M, et al. Effect of cyclooxygenase–2 inhibition with Vioxx (Rofecoxib).FDA Medical Officer`s Cardiovascular
rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary Review;22–23.httm://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b_06_cardio.p
artery disease. J. Am Coll Cardiol 2—3; 42: 1747–1753 df.2004
90. Bogaty P, Brophy JM, Noel M, et al. Impact of prolonged cycloxygenase–2 inhibition 116. Merk & Co. Response to article by Juni et al. published in the Lancet Nov 5, 2004.
on inflammatory markers and endothelial function in patients with ischemic heart disease httm://merck.com/statement_2004_1105/lancet.pdf.
and raised C–reactive protein. A randomized placebo0controlled study. Circulation 2004; 117. Davis NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and phar-
110: 934–939 makodynamics of celecoxib; a selective cyclo–oxygenase–2 inhibitor. Clin
91. Cippolone F, Toniato E, Martinotti S, et al. A polymorphism in the cyclooxygenase 2 Pharmacokinet 2000; 38: 225–242
gene as an inherited protective factor against myocardial infarction and stroke. JAMA 118. Davies NM, Teng XW, Skjodt NM. Pharmacokinetics of rofecoxib: a specific
2004; 291: 2221–2228 cyclooxygenase–2 inhibitor. Clin Pharmacokinet 2003; 42: 545–556.
92. Stiller C–O, Hjemdahl P. Endothelial COX–2 inhibition: possible relevance for hyper- 119. Hermann M, Shaw S, Kiss E, et al. Selective COX–2 inhibitors and renal injury in
tension and cardiovascular risk ?. J Hypertension 2003; 21: 1615–1618 salt–sensitive hypertension. Hypertension 2005;
93. Meune C, Mourad J–J, Bergmann J–B, Spaulding C. Interaction between cyclooxyge- 120. Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and
nase and the rennin–angiotensin–aldosterone system: rationale and clinical relevance. cardiovascular thromboembolic complications with meloxicam. Am J Med 2004; 117:
JRAAS 2003; 4: 149–154 100–106
94. Frishman WH. Effects of nonsteroidal anti–inflammatory drugs on blood pressure and 121. Mann J. Questioning the validity of the APPROVEe study`s official interpretation.
peripheral edema. Am J Cardiol 2002; 89: 18D–25D Assesses March 10, 2005.
95. Day R Hypertension in the patient with arthritis: have we been underestimating its sig- 122. Arthritis advisory committee. http:/www.fda.gov/ohtms/dockets/ac/cder0.5.html
nificance ? J Rheumatol 2003; 30:642–645 123. http:/www.rheumatology.org/publications/hotline/0305NSAIDs.asp.
96. Wolfe F, Zhao S, Reynolds M, Pettitt D. Blood ressure destabilization and edema 124. E??EIOIEE c.A. eAIEA ?OUAIOIOE·. eOOIAUAU IE A ?UEI OAIEA ‚OA-
among 8538 users of celecocib, rofecoxib, and nonselective nonsteroidal anti–inflamma- „O IIOO EI„E·EUO?O‚ ?EIIOOIOE„AIA? 2. Consilium Medicum 2005; 12 (6):
tory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J Rheumatol 918–925.
2004; 31: 1143–1151
97. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart
failure in eldery patient: an unrecognized public health problem. Arch Intern Medf 2000;
160: 777–784
98. Heerdink ER, Leufkens HG, Herings RMC, et al. NSAIDs associated with increased risk
of congestive heart failure in eldery patients taking diuretics. Arch Intern Med 1998; 158:
1108–1112
99. Feenstra J, Heerdink ER, Groobbee DE, Stricker BHC. Association of nonsteroidal
anti–inflammatory drugs with first occurrence of heart failure and with relapsing heart
failure; the Rotterdam study. Arch Intern Med 2002; 162: 265–270
100. Modena MG, Bonetti L, Coppi F, et al. Prognostic role of reversible endothelial dys-
function in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40: 505–510
101. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dys-
function in hypertensive patients. Circulation 2001; 104: 191–196
102. Wildansky ME, Price DT, Gokce N, et al. Short–and Long–Term COX–2 inhibition
reserves endothelial dysfunction in patients with hypertension. Hypertension 2003; 42:
310–315
103. Hermann M, Camici G, Fratton A, et al. Different effects of selective cyclooxyge-
nase–2 inhibitors on endothelial function in salt–induced hypertension. Circulation 2003;
108: 2308–2311
104. Bulut D, Liaghat S, Hanefeld C, et al. Selective cyclooxygenase–2 inhibition with
parecoxib acutely impairs endothelium–dependent vasodilatation in patients with essen-

<<

. 3
( 3 .)